{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:25:46Z","timestamp":1768274746775,"version":"3.49.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12519-025-00919-1","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T01:41:10Z","timestamp":1747446070000},"page":"430-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retinopathy of prematurity in the era of precision neonatology: from risk stratification to targeted therapies"],"prefix":"10.1007","volume":"21","author":[{"given":"Luca","family":"Filippi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Gulden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Cammalleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Araimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Cavallaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Villamor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40942-018-0125-z","volume":"4","author":"AM Freitas","year":"2018","unstructured":"Freitas AM, M\u00f6rschb\u00e4cher R, Thorell MR, Rhoden EL. Incidence and risk factors for retinopathy of prematurity: a retrospective cohort study. Int J Retina Vitreous. 2018;4:20.","journal-title":"Int J Retina Vitreous"},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1034\/j.1600-0420.1998.760216.x","volume":"76","author":"G Holmstr\u00f6m","year":"1998","unstructured":"Holmstr\u00f6m G, Broberger U, Thomassen P. Neonatal risk factors for retinopathy of prematurity\u2014a population-based study. Acta Ophthalmol Scand. 1998;76:204\u20137.","journal-title":"Acta Ophthalmol Scand"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77\u201382.","journal-title":"Early Hum Dev"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dmcn.15468","volume":"65","author":"O Dammann","year":"2023","unstructured":"Dammann O, Hartnett ME, Stahl A. Retinopathy of prematurity. Dev Med Child Neurol. 2023;65:625\u201331.","journal-title":"Dev Med Child Neurol"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1053\/j.semperi.2019.05.002","volume":"43","author":"C Gilbert","year":"2019","unstructured":"Gilbert C, Malik ANJ, Nahar N, Das SK, Visser L, Sitati S, et al. Epidemiology of ROP update\u2013Africa is the new frontier. Semin Perinatol. 2019;43:317\u201322.","journal-title":"Semin Perinatol"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"21977","DOI":"10.1038\/s41598-022-26229-4","volume":"12","author":"N de Las-Rivas-Ram\u00edrez","year":"2022","unstructured":"de Las-Rivas-Ram\u00edrez N, Luque-Aranda G, Rius-D\u00edaz F, P\u00e9rez-Fr\u00edas FJ, S\u00e1nchez-Tamayo T. Risk factors associated with retinopathy of prematurity development and progression. Sci Rep. 2022;12:21977.","journal-title":"Sci Rep"},{"key":"919_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1084-2756(98)80008-0","volume":"3","author":"OD Saugstad","year":"1998","unstructured":"Saugstad OD. Oxygen radical disease in neonatology. Semin Neonatol. 1998;3:229\u201338.","journal-title":"Semin Neonatol"},{"key":"919_CR8","doi-asserted-by":"publisher","first-page":"e3264","DOI":"10.1055\/a-2215-0662","volume":"41","author":"S El Emrani","year":"2024","unstructured":"El Emrani S, Jansen EJS, Goeman JJ, Lopriore E, Termote JUM, Schalij-Delfos NE, et al. Histological chorioamnionitis and funisitis as new risk factors for retinopathy of prematurity: a meta-analysis. Am J Perinatol. 2024;41:e3264\u201373.","journal-title":"Am J Perinatol"},{"key":"919_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205838","volume":"13","author":"E Villamor-Martinez","year":"2018","unstructured":"Villamor-Martinez E, Cavallaro G, Raffaeli G, Mohammed Rahim OMM, Gulden S, Ghazi AMT, et al. Chorioamnionitis as a risk factor for retinopathy of prematurity: an updated systematic review and meta-analysis. PLoS ONE. 2018;13:e0205838.","journal-title":"PLoS ONE"},{"key":"919_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/antiox12020534","volume":"12","author":"TM Hundscheid","year":"2023","unstructured":"Hundscheid TM, Huizing MJ, Villamor-Martinez E, Barto\u0161 F, Villamor E. Association of funisitis with short-term outcomes of prematurity: a frequentist and Bayesian meta-analysis. Antioxidants. 2023;12:534.","journal-title":"Antioxidants"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382:1445\u201357.","journal-title":"Lancet"},{"key":"919_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1111\/apa.15945","volume":"110","author":"O Dammann","year":"2021","unstructured":"Dammann O, Rivera JC, Chemtob S. The prenatal phase of retinopathy of prematurity. Acta Paediatr. 2021;110:2521\u20138.","journal-title":"Acta Paediatr"},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12519-023-00775-x","volume":"20","author":"TM Hundscheid","year":"2024","unstructured":"Hundscheid TM, Gulden S, Almutairi MF, Barto\u0161 F, Cavallaro G, Villamor E. Sex differences in the risk of retinopathy of prematurity: a systematic review, frequentist and Bayesian meta-analysis, and meta-regression. World J Pediatr. 2024;20:340\u201352.","journal-title":"World J Pediatr"},{"key":"919_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000444901","volume":"109","author":"R Cayabyab","year":"2016","unstructured":"Cayabyab R, Ramanathan R. Retinopathy of prematurity: therapeutic strategies based on pathophysiology. Neonatology. 2016;109:369\u201376.","journal-title":"Neonatology"},{"key":"919_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2019.109541","volume":"137","author":"W Podraza","year":"2020","unstructured":"Podraza W. A new approach to neonatal medical management that could transform the prevention of retinopathy of prematurity: theoretical considerations. Med Hypotheses. 2020;137:109541.","journal-title":"Med Hypotheses"},{"key":"919_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.710465","volume":"9","author":"E Priti\u0161anac","year":"2021","unstructured":"Priti\u0161anac E, Urlesberger B, Schwaberger B, Pichler G. Fetal hemoglobin and tissue oxygenation measured with near-infrared spectroscopy: a systematic qualitative review. Front Pediatr. 2021;9:710465.","journal-title":"Front Pediatr"},{"key":"919_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13052-024-01714-w","volume":"50","author":"L Teofili","year":"2024","unstructured":"Teofili L, Papacci P, Dani C, Cresi F, Remaschi G, Pellegrino C, et al. Cord blood transfusions in extremely low gestational age neonates to reduce severe retinopathy of prematurity: results of a prespecified interim analysis of the randomized BORN trial. Ital J Pediatr. 2024;50:142.","journal-title":"Ital J Pediatr"},{"key":"919_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.clp.2023.07.005","volume":"50","author":"L Teofili","year":"2023","unstructured":"Teofili L, Papacci P, Giannantonio C, Bianchi M, Giovanna Valentini C, Vento G. Allogenic cord blood transfusion in preterm infants. Clin Perinatol. 2023;50:881\u201393.","journal-title":"Clin Perinatol"},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/pr.2016.98","volume":"80","author":"R Cayabyab","year":"2016","unstructured":"Cayabyab R, Arora V, Wertheimer F, Durand M, Ramanathan R. Graded oxygen saturation targets and retinopathy of prematurity in extremely preterm infants. Pediatr Res. 2016;80:401\u20136.","journal-title":"Pediatr Res"},{"key":"919_CR20","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1542\/peds.2009-2218","volume":"125","author":"ML Chen","year":"2010","unstructured":"Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010;125:e1483\u201392.","journal-title":"Pediatrics"},{"key":"919_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.semperi.2019.05.004","volume":"43","author":"BA Darlow","year":"2019","unstructured":"Darlow BA, Husain S. Primary prevention of ROP and the oxygen saturation targeting trials. Semin Perinatol. 2019;43:333\u201340.","journal-title":"Semin Perinatol"},{"key":"919_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1001\/jamaophthalmol.2018.7021","volume":"137","author":"A Shukla","year":"2019","unstructured":"Shukla A, Sonnie C, Worley S, Sharma A, Howard D, Moore J, et al. Comparison of biphasic vs static oxygen saturation targets among infants with retinopathy of prematurity. JAMA Ophthalmol. 2019;137:417\u201323.","journal-title":"JAMA Ophthalmol"},{"key":"919_CR23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-053924","volume":"150","author":"K Sabri","year":"2022","unstructured":"Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of prematurity: a global perspective and recent developments. Pediatrics. 2022;150:e2021053924.","journal-title":"Pediatrics"},{"key":"919_CR24","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s40123-023-00744-7","volume":"12","author":"ME Hartnett","year":"2023","unstructured":"Hartnett ME, Stahl A. Laser versus anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity. Ophthalmol Ther. 2023;12:2241\u201352.","journal-title":"Ophthalmol Ther"},{"key":"919_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.922303","volume":"10","author":"X Xie","year":"2022","unstructured":"Xie X, Wang Y, Zhao R, Yang J, Zhu X, Ouyang L, et al. Refractive status and optical components in premature infants with and without retinopathy of prematurity: a 4- to 5-year cohort study. Front Pediatr. 2022;10:922303.","journal-title":"Front Pediatr"},{"key":"919_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.113913","volume":"273","author":"CC Lee","year":"2024","unstructured":"Lee CC, Chiang MC, Chu SM, Wu WC, Ho MM, Lien R. Clinical risk factors for retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor injection. J Pediatr. 2024;273:113913.","journal-title":"J Pediatr"},{"key":"919_CR27","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Dumas-Roque E, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649\u201351.","journal-title":"N Engl J Med"},{"key":"919_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117181","volume":"178","author":"S Xiang","year":"2024","unstructured":"Xiang S, Gong X, Qiu T, Zhou J, Yang K, Lan Y, et al. Insights into the mechanisms of angiogenesis in infantile hemangioma. Biomed Pharmacother. 2024;178:117181.","journal-title":"Biomed Pharmacother"},{"key":"919_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/archdermatol.2010.1295","volume":"146","author":"BA Drolet","year":"2010","unstructured":"Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Arch Dermatol. 2010;146:1295\u20139.","journal-title":"Arch Dermatol"},{"key":"919_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bjo.87.3.275","volume":"87","author":"PE North","year":"2003","unstructured":"North PE, Anthony DC, Young TL, Waner M, Brown HH, Brodsky MC. Retinal neovascular markers in retinopathy of prematurity: aetiological implications. Br J Ophthalmol. 2003;87:275\u20138.","journal-title":"Br J Ophthalmol"},{"key":"919_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1747-1028-8-1","volume":"8","author":"Y Ji","year":"2013","unstructured":"Ji Y, Chen S, Li K, Xiao X, Zheng S, Xu T. The role of \u03b2-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div. 2013;8:1.","journal-title":"Cell Div"},{"key":"919_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2431-10-83","volume":"10","author":"L Filippi","year":"2010","unstructured":"Filippi L, Cavallaro G, Fiorini P, Daniotti M, Benedetti V, Cristofori G, et al. Study protocol: safety and efficacy of propranolol in newborns with retinopathy of prematurity (PROP-ROP): isrctn18523491. BMC Pediatr. 2010;10:83.","journal-title":"BMC Pediatr"},{"key":"919_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/med.21336","volume":"35","author":"L Filippi","year":"2015","unstructured":"Filippi L, Dal Monte M, Casini G, Daniotti M, Sereni F, Bagnoli P. Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the \u03b2-adrenergic system. Med Res Rev. 2015;35:619\u201352.","journal-title":"Med Res Rev"},{"key":"919_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1471-4159.2011.07530.x","volume":"119","author":"D Martini","year":"2011","unstructured":"Martini D, Monte MD, Ristori C, Cupisti E, Mei S, Fiorini P, et al. Antiangiogenic effects of \u03b22 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119:1317\u201329.","journal-title":"J Neurochem"},{"key":"919_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1167\/iovs.10-5536","volume":"52","author":"C Ristori","year":"2011","unstructured":"Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52:155\u201370.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"919_CR36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fncel.2017.00395","volume":"11","author":"M Cammalleri","year":"2017","unstructured":"Cammalleri M, Locri F, Catalani E, Filippi L, Cervia D, Dal Monte M, et al. The beta adrenergic receptor blocker propranolol counteracts retinal dysfunction in a mouse model of oxygen induced retinopathy: restoring the balance between apoptosis and autophagy. Front Cell Neurosci. 2017;11:395.","journal-title":"Front Cell Neurosci"},{"key":"919_CR37","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","volume":"163","author":"L Filippi","year":"2013","unstructured":"Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Donzelli G, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163:1570\u20137.e6.","journal-title":"J Pediatr"},{"key":"919_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/archdischild-2013-303951","volume":"98","author":"IR Makhoul","year":"2013","unstructured":"Makhoul IR, Peleg O, Miller B, Bar-Oz B, Kochavi O, Mechoulam H, et al. Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study. Arch Dis Child. 2013;98:565\u20137.","journal-title":"Arch Dis Child"},{"key":"919_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1515\/jpm-2015-0357","volume":"44","author":"A Bancalari","year":"2016","unstructured":"Bancalari A, Schade R, Mu\u00f1oz T, Lazcano C, Parada R, Pe\u00f1a R. Oral propranolol in early stages of retinopathy of prematurity. J Perinat Med. 2016;44:499\u2013503.","journal-title":"J Perinat Med"},{"key":"919_CR40","doi-asserted-by":"publisher","first-page":"F389","DOI":"10.1136\/archdischild-2016-311548","volume":"102","author":"KP Sanghvi","year":"2017","unstructured":"Sanghvi KP, Kabra NS, Padhi P, Singh U, Dash SK, Avasthi BS. Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial). Arch Dis Child Fetal Neonatal Ed. 2017;102:F389\u201394.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"919_CR41","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s10792-018-1018-8","volume":"39","author":"MA Ozturk","year":"2019","unstructured":"Ozturk MA, Korkmaz L. The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: which newborn and when? Int Ophthalmol. 2019;39:1921\u201330.","journal-title":"Int Ophthalmol"},{"key":"919_CR42","first-page":"266","volume":"33","author":"H Sun","year":"2018","unstructured":"Sun H, Li MC, Yu ZY, Xing S, Yuan MM, Cheng P. The efficacy and safety of oral propranolol in the treatment of retinopathy of prematurity. Chin J Neonatol. 2018;33:266\u201370.","journal-title":"Chin J Neonatol"},{"key":"919_CR43","first-page":"1","volume":"14","author":"P Mohammadi","year":"2023","unstructured":"Mohammadi P, Babaei H, Mohsenpour H, Azadi P. Efficacy of oral propranolol in prevention of severe retinopathy of prematurity: a randomized clinical trial study. Iran J Neonatol. 2023;14:1\u20137.","journal-title":"Iran J Neonatol"},{"key":"919_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.34172\/cjmb.2022.10","volume":"9","author":"M Hosseini","year":"2022","unstructured":"Hosseini M, Mostafa Gharebaghi M, Bagheri M, Yeganehdoost S, Eftekhari Milani A, Niyousha MR. Efficacy of oral propranolol on the treatment of retinopathy of prematurity. Crescent J Med Biol Sci. 2022;9:56\u201362.","journal-title":"Crescent J Med Biol Sci"},{"key":"919_CR45","first-page":"CD011893","volume":"3","author":"S Kaempfen","year":"2018","unstructured":"Kaempfen S, Neumann RP, Jost K, Schulzke SM. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2018;3:CD011893.","journal-title":"Cochrane Database Syst Rev"},{"key":"919_CR46","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41372-019-0503-x","volume":"39","author":"A Stritzke","year":"2019","unstructured":"Stritzke A, Kabra N, Kaur S, Robertson HL, Lodha A. Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2019;39:1584\u201394.","journal-title":"J Perinatol"},{"key":"919_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.631673","volume":"9","author":"HB Kong","year":"2021","unstructured":"Kong HB, Zheng GY, He BM, Zhang Y, Zhou Q. Clinical efficacy and safety of propranolol in the prevention and treatment of retinopathy of prematurity: a meta-analysis of randomized controlled trials. Front Pediatr. 2021;9:631673.","journal-title":"Front Pediatr"},{"key":"919_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajo.2023.11.012","volume":"259","author":"MA Shafique","year":"2024","unstructured":"Shafique MA, Haseeb A, Uddin MMN, Asghar B, Chaudhry ER, Raqib MA, et al. Effectiveness of propranolol in preventing severe retinopathy of prematurity: a comprehensive systematic review and meta-analysis. Am J Ophthalmol. 2024;259:141\u201350.","journal-title":"Am J Ophthalmol"},{"key":"919_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.exer.2013.03.013","volume":"111","author":"M Dal Monte","year":"2013","unstructured":"Dal Monte M, Casini G, la Marca G, Isacchi B, Filippi L, Bagnoli P. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Eye Res. 2013;111:27\u201335.","journal-title":"Exp Eye Res"},{"key":"919_CR50","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/pr.2014.108","volume":"76","author":"L Padrini","year":"2014","unstructured":"Padrini L, Isacchi B, Bilia AR, Pini A, Lanzi C, Masini E, et al. Pharmacokinetics and local safety profile of propranolol eye drops in rabbits. Pediatr Res. 2014;76:378\u201385.","journal-title":"Pediatr Res"},{"key":"919_CR51","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fped.2019.00180","volume":"7","author":"L Filippi","year":"2019","unstructured":"Filippi L, Cavallaro G, Berti E, Padrini L, Araimo G, Regiroli G, et al. Propranolol 0.2% eye micro-drops for retinopathy of prematurity: a prospective phase IIB study. Front Pediatr. 2019;7:180.","journal-title":"Front Pediatr"},{"key":"919_CR52","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/apa.16850","volume":"112","author":"RT Scaramuzzo","year":"2023","unstructured":"Scaramuzzo RT, Bagnoli P, Dal Monte M, Cammalleri M, Pini A, Ballini S, et al. Treating infants with 0.2% propranolol eye micro-drops drastically reduced the progression of retinopathy of prematurity. Acta Paediatr. 2023;112:1905\u20136.","journal-title":"Acta Paediatr"},{"key":"919_CR53","doi-asserted-by":"publisher","first-page":"1408605","DOI":"10.3389\/fphys.2024.1408605","volume":"15","author":"M Cammalleri","year":"2024","unstructured":"Cammalleri M, Filippi L, Dal Monte M, Bagnoli P. A promising case of preclinical-clinical translation: \u03b2-adrenoceptor blockade from the oxygen-induced retinopathy model to retinopathy of prematurity. Front Physiol. 2024;15:1408605.","journal-title":"Front Physiol"},{"key":"919_CR54","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/med.22092","volume":"45","author":"L Filippi","year":"2025","unstructured":"Filippi L, Innocenti F, Pascarella F, Scaramuzzo RT, Morganti R, Bagnoli P, et al. \u03b23-adrenoceptor agonism to mimic the biological effects of intrauterine hypoxia: taking great strides toward a pharmacological artificial placenta. Med Res Rev. 2025;45:842\u201366.","journal-title":"Med Res Rev"},{"key":"919_CR55","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1126\/science.2570461","volume":"245","author":"LJ Emorine","year":"1989","unstructured":"Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989;245:1118\u201321.","journal-title":"Science"},{"key":"919_CR56","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1161\/01.CIR.103.12.1649","volume":"103","author":"S Moniotte","year":"2001","unstructured":"Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of \u03b23-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001;103:1649\u201355.","journal-title":"Circulation"},{"key":"919_CR57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/hh1901.098042","volume":"89","author":"HJ Cheng","year":"2001","unstructured":"Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP. Upregulation of functional \u03b23-adrenergic receptor in the failing canine myocardium. Circ Res. 2001;89:599\u2013606.","journal-title":"Circ Res"},{"key":"919_CR58","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/cells11081271","volume":"11","author":"R Amato","year":"2022","unstructured":"Amato R, Pisani F, Laudadio E, Cammalleri M, Lucchesi M, Marracci S, et al. HIF-1-dependent induction of \u03b23 adrenoceptor: evidence from the mouse retina. Cells. 2022;11:1271.","journal-title":"Cells"},{"key":"919_CR59","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/med.21874","volume":"42","author":"L Filippi","year":"2022","unstructured":"Filippi L, Pini A, Cammalleri M, Bagnoli P, Dal Monte M. \u03b23-Adrenoceptor, a novel player in the round-trip from neonatal diseases to cancer: suggestive clues from embryo. Med Res Rev. 2022;42:1179\u2013201.","journal-title":"Med Res Rev"},{"key":"919_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106713","volume":"190","author":"M Cammalleri","year":"2023","unstructured":"Cammalleri M, Amato R, Dal Monte M, Filippi L, Bagnoli P. The \u03b23 adrenoceptor in proliferative retinopathies: \u201cCinderella\u201d steps out of its family shadow. Pharmacol Res. 2023;190:106713.","journal-title":"Pharmacol Res"},{"key":"919_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00210-012-0828-x","volume":"386","author":"M Dal Monte","year":"2013","unstructured":"Dal Monte M, Filippi L, Bagnoli P. Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedeberg\u2019s Arch Pharmacol. 2013;386:269\u201378.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"919_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1167\/iovs.65.10.34","volume":"65","author":"A Melecchi","year":"2024","unstructured":"Melecchi A, Canovai A, Amato R, Dal Monte M, Filippi L, Bagnoli P, et al. Agonism of \u03b23-adrenoceptors inhibits pathological retinal angiogenesis in the model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2024;65:34.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"919_CR63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/glia.20900","volume":"58","author":"MI Dorrell","year":"2010","unstructured":"Dorrell MI, Aguilar E, Jacobson R, Trauger SA, Friedlander J, Siuzdak G, et al. Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia. 2010;58:43\u201354.","journal-title":"Glia"},{"key":"919_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tcm.2009.04.004","volume":"19","author":"Y Kubota","year":"2009","unstructured":"Kubota Y, Suda T. Feedback mechanism between blood vessels and astrocytes in retinal vascular development. Trends Cardiovasc Med. 2009;19:38\u201343.","journal-title":"Trends Cardiovasc Med"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00919-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-025-00919-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00919-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T18:02:01Z","timestamp":1750010521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-025-00919-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1007\/s12519-025-00919-1","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"17 May 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}